Compelling Benefit of Soluble Suppression of Tumorigenicity‐2 in Post–Myocardial Infarction Estimation of Risk: The Time Is Right for Its Routine Use in the Clinic

Journal of the American Heart Association

  ^{1    2} 

[1] Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain;Heart Institute, Hospital Universitari Germans Trias i Pujol, Badalona, Spain;Department of Medicine, Autonomous University of Barcelona, Barcelona, Spain;Program of Cardiovascular Diseases, Center for Applied Medical Research, University of Navarra, Pamplona, Spain;Department of Cardiology and Cardiac Surgery, University Clinic, University of Navarra, Pamplona, Spain;Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain;

关键词: Editorials;    biomarker;    myocardial infarction;    ST;    risk stratification;    ST;   

DOI  :  10.1161/JAHA.117.007665

来源: publisher

【 授权许可】

Unknown